Warning:
JavaScript is turned OFF. None of the links on this page will work until it is reactivated.
If you need help turning JavaScript On, click here.
This Concept Map, created with IHMC CmapTools, has information related to: Ch 16 merged, Phase III Clinical Trials are performed in Phase IV Clinical Trials, Acte promyelocytic leukemia (APL) results by fusion protein PML-RAR, ubiquitinylated IkB is not degraded in the presence of Velcade, degredation of protiens by the proteasome, Phase III Clinical Trials test a Large Population, Specific cancer therapies 16.2 eg rapamycin targetting mTOR 16.15, Stereochemistry must allow the drug to fit in the Specific Target Proteins, mTOR (mammalian target of rapamycin) associates with Rictor, Rapamycin associates with and shuts down mTOR (mammalian target of rapamycin), Proteasome inhibitors eg Velcade, Velcade was originally developed to combat problem of cachexia, Drug Resistance can be shown in her2 Transgenic Mice, Velcade slows down passage thru proteasome, Pre-clinical Studies can dictate the need for Derivatization, Specific cancer therapies 16.2 can only target certain Biochemical properties of proteins 16.4, Rictor and the complex activates Akt/PKB, EGF-R in tumors can cause Oncogenic Signaling, teratogen eg cyclopamine, Specific cancer therapies 16.2 can only target certain Defective protein subsets 16.3, holoprosencephaly eg abnormal development of bilaterally symmetrical structures in embryonic head